TBTimothy Bergquist

Timothy Bergquist

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Timothy Bergquist has a total of 266 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A Genome-First Study of Familial Hypercholesterolemia Comparing African and European Ancestry Individuals

    by Alexandra H. Winters, Melissa A. Kelly, Mohammad Ghouse Syed, Timothy Bergquist, Alexander S.F. Berry, Nuha Mohammed, Dylan Cawley, Laney K. Jones, Vikas Pejaver, Samuel S. Gidding, et al.

    BACKGROUND: Familial hypercholesterolemia (FH) is an inherited disorder characterized by lifelong elevated LDL-C (low-density lipoprotein cholesterol) and increased risk for premature myocardial infarction. FH research has focused on European populations and, consequently, estimates of global FH burden primarily reflect this ancestry, with limited data available from other groups. METHODS: We examined the prevalence and clinical outcomes of FH among 104 300 African ancestry individuals enrolled in 3 US-based cohorts: the National Institutes of Health’s All of Us, Mount Sinai’s BioMe, and Geisinger’s MyCode. Genetic variants were evaluated according to standards provided by the Clinical Genome Resource’s FH Variant Curation Expert Panel and grouped as pathogenic variants or variants of unknown significance (VUSs). Participants were assigned to European and African ancestry groups based on genetic similarity to reference populations. Clinical outcomes were LDL-C and myocardial infarction. Analyses were adjusted for age and sex. Results were meta-analyzed across cohorts. RESULTS: The prevalence of a pathogenic variant was similar in the African (1 in 306) and European (1 in 273) ancestry groups. The LDL-C elevation associated with pathogenic variants was 20.81 mg/dL (95% CI, 16.17–25.45) greater in individuals with African ancestry compared with their counterparts with European ancestry. Individuals with African ancestry had 1.61 (95% CI, 1.42–1.83; P =1.2×10 -12 ) higher odds of having a VUS compared with individuals with European ancestry and a 10.01 mg/dL (95% CI, 6.13–13.88) greater elevation in LDL-C compared with individuals with European ancestry with a VUS. Although pathogenic variants in both ancestries conferred a 2- to 3-fold increased risk of myocardial infarction, having a VUS only conferred increased risk among the African ancestry group (odds ratio, 1.91 [95% CI, 1.18–3.10]). CONCLUSIONS: The prevalence of pathogenic variants did not significantly vary between African and European ancestry groups. VUSs were both more prevalent among individuals of African ancestry and associated with an increased risk of myocardial infarction equivalent to that of a pathogenic variant. These findings suggest that dependence on existing resources for variant classification could contribute to underdiagnosis of FH in individuals of African ancestry.

  • Open Access

    Calibration of in-frame indel variant effect predictors for clinical variant classification

    by Haneen Abderrazzaq, Mugdha Singh, Larry Babb, Timothy Bergquist, Steven E. Brenner, Vikas Pejaver, Anne O’DOnnell-Luria, Predrag Radivojac

    Insertions and deletions (indels) represent a substantial source of genetic variation in humans and are associated with a diverse array of functional consequences. Despite their prevalence and clinical importance, indels, particularly short in-frame indels, remain critically understudied compared to single nucleotide variants and are challenging to interpret clinically. While many computational predictors for missense variants have been rigorously evaluated and calibrated for clinical use, the clinical utility of tools for in-frame indels remains uncertain. To address this gap, we have calibrated in-frame indel prediction tools for clinical variant classification. We constructed a high-confidence dataset of in-frame indel variants (≤ 50bp) from clinical and population databases and estimated the prior probability of pathogenicity of a rare in-frame indel observed in a disease-associated gene, and of an insertion and deletion separately. Using a previously developed statistical framework based on local posterior probabilities, we then established score thresholds for eight computational tools, corresponding to distinct evidence levels for pathogenic and benign classification according to ACMG/AMP guidelines. All in-frame indel predictors evaluated here reached multiple evidence levels of pathogenicity and/or benignity, demonstrating measurable clinical value. However, these models consistently exhibited lower performance levels compared to missense predictors, highlighting the need for improved computational approaches for indel classification.


  • Open Access

    Gene- and domain-aware calibration increases the clinical utility of variant effect predictors

    by Yile Chen, Shawn Fayer, Shantanu Jain, Mariam Benazouz, Yuriy Sverchkov, Jeremy Stone, Himanshu Sharma, Timothy Bergquist, Ross Stewart, Sean D. Mooney, et al.

    The utility of clinical genetic testing is limited because around 90% of missense variants in ClinVar remain of uncertain clinical significance. Variant effect predictors (VEPs) can score any missense variant, potentially empowering variant classification. Realizing this potential requires calibration to translate predictor scores into evidence. However, genome-wide calibration ignores predictor heterogeneity across genes, causing evidence misassignment. We developed an automated, data-adaptive framework that optimizes two complementary approaches: gene-specific calibration for genes with enough variants for calibration, and domain-aggregate calibration for other disease-associated genes, which groups variants from protein domains with similar predictor score distributions for calibration. Applied to three predictors across 2,769 genes, this framework assigned evidence to 10.6% more variants on average while generally improving evidence accuracy compared to genome-wide calibration. These calibrations and the resulting calibrated computational evidence are available through the PredictMD portal. Our framework substantially increases the clinical utility of VEPs for variant classification.


  • Top Cited Papers
    Open Access

    Calibration of additional computational tools expands ClinGen recommendation options for variant classification with PP3/BP4 criteria

    by Timothy Bergquist, Sarah L. Stenton, Emily A.W. Nadeau, Alicia B. Byrne, Marc S. Greenblatt, Steven M. Harrison, Sean V. Tavtigian, Anne O'DOnnell-Luria, Leslie G. Biesecker, Predrag Radivojac, et al.


  • Open Access

    Calibration of additional computational tools expands ClinGen recommendation options for variant classification with PP3/BP4 criteria

    by Timothy Bergquist, Sarah L. Stenton, Emily A.W. Nadeau, Alicia B. Byrne, Marc S. Greenblatt, Steven M. Harrison, Sean V. Tavtigian, Anne O’donnell-Luria, Leslie G. Biesecker, Predrag Radivojac, et al.

    Purpose: We previously developed an approach to calibrate computational tools for clinical variant classification, updating recommendations for the reliable use of variant impact predictors to provide evidence strength up to Strong . A new generation of tools using distinctive approaches have since been released, and these methods must be independently calibrated for clinical application. Method: Using our local posterior probability-based calibration and our established data set of ClinVar pathogenic and benign variants, we determined the strength of evidence provided by three new tools (AlphaMissense, ESM1b, VARITY) and calibrated scores meeting each evidence strength. Results All three tools reached the Strong level of evidence for variant pathogenicity and Moderate for benignity, though sometimes for few variants. Compared to previously recommended tools, these yielded at best only modest improvements in the tradeoffs of evidence strength and false positive predictions. Conclusion: At calibrated thresholds, three new computational predictors provided evidence for variant pathogenicity at similar strength to the four previously recommended predictors (and comparable with functional assays for some variants). This calibration broadens the scope of computational tools for application in clinical variant classification. Their new approaches offer promise for future advancement of the field.


  • Open Access

    Assessment of the evidence yield for the calibrated PP3/BP4 computational recommendations

    by Sarah L. Stenton, Vikas Pejaver, Timothy Bergquist, Leslie G. Biesecker, Alicia B. Byrne, Emily Nadeau, Marc S. Greenblatt, Steven Harrison, Sean Tavtigian, Predrag Radivojac, et al.

    Purpose To investigate the number of rare missense variants observed in human genome sequences by ACMG/AMP PP3/BP4 evidence strength, following the calibrated PP3/BP4 computational recommendations. Methods Missense variants from the genome sequences of 300 probands from the Rare Genomes Project with suspected rare disease were analyzed using computational prediction tools able to reach PP3_Strong and BP4_Moderate evidence strengths (BayesDel, MutPred2, REVEL, and VEST4). The numbers of variants at each evidence strength were analyzed across disease-associated genes and genome-wide. Results From a median of 75.5 rare (≤1% allele frequency) missense variants in disease-associated genes per proband, a median of one reached PP3_Strong, 3-5 PP3_Moderate, and 3-5 PP3_Supporting. Most were allocated BP4 evidence (median 41-49 per proband) or were indeterminate (median 17.5-19 per proband). Extending the analysis to all protein-coding genes genome-wide, the number of PP3_Strong variants increased approximately 2.6-fold compared to disease-associated genes, with a median per proband of 1-3 PP3_Strong, 8-16 PP3_Moderate, and 10-17 PP3_Supporting. Conclusion A small number of variants per proband reached PP3_Strong and PP3_Moderate in 3,424 disease-associated genes, and though not the intended use of the recommendations, also genome-wide. Use of PP3/BP4 evidence as recommended from calibrated computational prediction tools in the clinical diagnostic laboratory is unlikely to inappropriately contribute to the classification of an excessive number of variants as Pathogenic or Likely Pathogenic by ACMG/AMP rules.


  • Evaluation of crowdsourced mortality prediction models as a framework for assessing artificial intelligence in medicine

    by Timothy Bergquist, Thomas Schaffter, Yao Yan, Thomas Yu, Justin Prosser, Jifan Gao, Guanhua Chen, Łukasz Charzewski, Zofia Nawalany, Ivan Brugere, et al.

    Applications of machine learning in healthcare are of high interest and have the potential to improve patient care. Yet, the real-world accuracy of these models in clinical practice and on different patient subpopulations remains unclear. To address these important questions, we hosted a community challenge to evaluate methods that predict healthcare outcomes. We focused on the prediction of all-cause mortality as the community challenge question. Using a Model-to-Data framework, 345 registered participants, coalescing into 25 independent teams, spread over 3 continents and 10 countries, generated 25 accurate models all trained on a dataset of over 1.1 million patients and evaluated on patients prospectively collected over a 1-year observation of a large health system. The top performing team achieved a final area under the receiver operator curve of 0.947 (95% CI, 0.942-0.951) and an area under the precision-recall curve of 0.487 (95% CI, 0.458-0.499) on a prospectively collected patient cohort. Post hoc analysis after the challenge revealed that models differ in accuracy on subpopulations, delineated by race or gender, even when they are trained on the same data. This is the largest community challenge focused on the evaluation of state-of-the-art machine learning methods in a healthcare system performed to date, revealing both opportunities and pitfalls of clinical AI.


  • Top Cited Papers
    Open Access

    Federated benchmarking of medical artificial intelligence with MedPerf

    by Alexandros Karargyris, Renato Umeton, Micah J. Sheller, Alejandro Aristizabal, Johnu George, Anna Wuest, Sarthak Pati, Hasan Kassem, Maximilian Zenk, Ujjwal Baid, et al.

    Medical artificial intelligence (AI) has tremendous potential to advance healthcare by supporting and contributing to the evidence-based practice of medicine, personalizing patient treatment, reducing costs, and improving both healthcare provider and patient experience. Unlocking this potential requires systematic, quantitative evaluation of the performance of medical AI models on large-scale, heterogeneous data capturing diverse patient populations. Here, to meet this need, we introduce MedPerf, an open platform for benchmarking AI models in the medical domain. MedPerf focuses on enabling federated evaluation of AI models, by securely distributing them to different facilities, such as healthcare organizations. This process of bringing the model to the data empowers each facility to assess and verify the performance of AI models in an efficient and human-supervised process, while prioritizing privacy. We describe the current challenges healthcare and AI communities face, the need for an open platform, the design philosophy of MedPerf, its current implementation status and real-world deployment, our roadmap and, importantly, the use of MedPerf with multiple international institutions within cloud-based technology and on-premises scenarios. Finally, we welcome new contributions by researchers and organizations to further strengthen MedPerf as an open benchmarking platform.


  • Open Access

    A framework for future national pediatric pandemic respiratory disease severity triage: The HHS pediatric COVID-19 data challenge

    by Timothy Bergquist, Marie Wax, Tellen D. Bennett, Richard A. Moffitt, Jifan Gao, Guanhua Chen, Amalio Telenti, M. Cyrus Maher, Istvan Bartha, Lorne Walker, et al.

    Introduction: With persistent incidence, incomplete vaccination rates, confounding respiratory illnesses, and few therapeutic interventions available, COVID-19 continues to be a burden on the pediatric population. During a surge, it is difficult for hospitals to direct limited healthcare resources effectively. While the overwhelming majority of pediatric infections are mild, there have been life-threatening exceptions that illuminated the need to proactively identify pediatric patients at risk of severe COVID-19 and other respiratory infectious diseases. However, a nationwide capability for developing validated computational tools to identify pediatric patients at risk using real-world data does not exist. Methods: HHS ASPR BARDA sought, through the power of competition in a challenge, to create computational models to address two clinically important questions using the National COVID Cohort Collaborative: (1) Of pediatric patients who test positive for COVID-19 in an outpatient setting, who are at risk for hospitalization? (2) Of pediatric patients who test positive for COVID-19 and are hospitalized, who are at risk for needing mechanical ventilation or cardiovascular interventions? Results: This challenge was the first, multi-agency, coordinated computational challenge carried out by the federal government as a response to a public health emergency. Fifty-five computational models were evaluated across both tasks and two winners and three honorable mentions were selected. Conclusion: This challenge serves as a framework for how the government, research communities, and large data repositories can be brought together to source solutions when resources are strapped during a pandemic.


  • Major risk factors associated with severe COVID-19 outcomes in patients with multiple myeloma: Report from the National COVID-19 Cohort Collaborative (N3C).

    by Amit Kumar Mitra, Ujjal Mukherjee, Suman Mazumder, Vithal Madhira, Timothy Bergquist, Yu Shao, Feifan Liu, Qianqian Song, Jing Su, Benjamin Bates, et al.

    8008 Background: Patients with multiple myeloma (MM), an age-dependent neoplasm of antibody-producing plasma cells, have compromised immune systems due to multiple factors that may increase the risk of severe COVID-19. The NCATS’ National COVID Cohort Collaborative (N3C) is a centralized data resource representing the largest multi-center cohort of ̃12M COVID-19 cases and controls nationwide. In this study, we aim to analyze risk factors associated with COVID-19 severity and death in MM patients using the N3C database. Methods: Our cohort included MM patients within the N3C registry diagnosed with COVID-19 based on positive PCR or antigen tests or ICD-10–CM. The outcomes of interest include all-cause mortality (including discharge to hospice) during the index encounter, and clinical indicators of severity (hospitalization/ED visit, use of mechanical ventilation, or extracorporeal membrane oxygenation/ECMO). Results: As of 09/10/2021, the N3C registry included 690371 cancer patients, out of which 17791 were MM patients (4707 were COVID-19+). The mean age at diagnosis was 65.9yrs, 57.6% were >65yo, 46.4% were females, and 21.8% were Blacks. 25.6% had a Charlson Comorbidity Index (CCI) score of ≥2. 55.6% required an inpatient or ED visit, and 3.65% required invasive ventilation. 11.4% developed acute kidney injury during hospitalization. Multivariate logistic regression analysis showed histories of pulmonary disease (OR 2.2; 95%CI: 1.7-2.8), renal disease (OR 1.8; 95%CI: 1.4-2.4), and black race (p<0.001) were associated with higher risk of severity. Interestingly, smoking status was significantly associated with a lower risk of severity (OR 0.7; 95%CI: 0.5-0.9). Further, protective association was also observed between COVID-19 severity and blood or marrow transplant (BMT) (OR 0.52; 95%CI: 0.4-0.7), daratumumab therapy (OR 0.64; 95%CI: 0.42-0.99) and COVID-19 vaccination (OR 0.28; 95%CI: 0.18-0.44). IMiDs were associated increase in the risk of COVID-19 severity (OR 2.1; 95%CI: 1.6-2.7). 2.3% of N3C-myeloma COVID-19+ patients died within the first 10 days, while 4.95% died within 30 days of COVID-19 hospitalization. Overall, the survival probability was 90.5% across the course of the study. Multivariate cox proportional hazard model showed that CCI score ≥2 (HR 4.4; 95%CI: 2.2-8.8), hypertension (HR 1.6; 95%CI: 1.02-2.4), IMiD (HR 2.6; 95%CI: 1.8-3.8) and proteasome inhibitor (HR 1.6; 95%CI: 1.1-2.5) therapy were associated with worse survival. COVID-19 vaccination (HR 0.195; 95%CI: 0.09-0.45) and BMT (HR 0.65; 95%CI: 0.4-0.995) were associated with lower risk of death. Conclusions: We have identified previously unpublished potential risk factors for COVID-19 severity and death in MM as well as validated some published ones. To the best of our knowledge, this is the largest nationwide study on multiple myeloma patients with COVID-19.